

## Membrane Pathology in Schizophrenia: Implication for Arachidonic Acid Signaling

Jeffrey K. Yao<sup>1,2,3,\*</sup> and Ravinder D. Reddy<sup>3</sup>

<sup>1</sup>VA Pittsburgh Healthcare System, 7180 Highland Drive, Pittsburgh, PA 15206;

<sup>2</sup>Department of Psychiatry, University of Pittsburgh Medical Center; <sup>3</sup>Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213

E-mail: [jkyao@pitt.edu](mailto:jkyao@pitt.edu); [reddyr@msx.upmc.edu](mailto:reddyr@msx.upmc.edu)

Received March 12, 2002; Accepted June 3, 2002; Published July 10, 2002

---

Schizophrenia is a major mental disorder with no clearly identified pathophysiology. A variety of theories has been proposed to explain the pathophysiology of schizophrenia. One approach that is finding empirical support is the investigation of membrane composition and function. Evidence to date suggests that there are defects in phospholipid metabolism and cell signaling in schizophrenia. Specifically, low levels of arachidonic acid (AA)-enriched phospholipids have been observed in both central and peripheral tissues. It is well known that changes in membrane composition are associated with a variety of functional consequences. Since AA has many key roles in neural functioning, understanding its significance for the pathophysiology of schizophrenia may lead to novel approaches to improving treatment of schizophrenia. The purpose of this review is thus to explore some of the roles of AA signaling in biological, physiological, and clinical phenomena observed in schizophrenia.

**KEY WORDS:** schizophrenia, arachidonic acid, phospholipid metabolism, neurotransmission, phosphoinositide signaling system, eicosanoids, endocannabinoids, ethyl eicosapentaenoate supplementation

**DOMAINS:** neuroscience, psychiatry, metabolism, signaling, transmembrane signaling, biochemistry, psychopharmacology, analytical chemistry

---

### INTRODUCTION

Schizophrenia is a complex disorder. Research over the last century has suggested that neuronal maldevelopment, impaired neurotransmission, intrauterine viral infections, autoimmune dysfunc-

tion, and many other mechanisms may underlie the pathophysiology of schizophrenia. There are a large variety of seemingly disparate biological findings[1], possibly due to etiologic heterogeneity. This would suggest that there are one or more (but very few) common pathogenetic pathways that lead to the syndromes of schizophrenia. Thus, there is need to identify pathological process(es) that can explain many of the clinical and biological features in schizophrenia.

There is substantial evidence for both peripheral and central membrane abnormalities in patients with *chronic* schizophrenia, and a relative paucity of such evidence in early schizophrenia[2]. One of the key findings in the RBC membrane is decreased polyunsaturated fatty acids (PUFAs), particularly arachidonic acid (AA). Further, alterations in AA are associated with membrane dysfunction of clinical relevance. This defect appears to be independent of neuroleptic treatment (based on findings from drug free and neuroleptic-naive patients), and is associated with illness severity. The primary mechanisms that may lead to reduced membrane AA are increased phospholipid hydrolysis and/or decreased incorporation. The accelerated breakdown of membrane phospholipids is indirectly supported by the <sup>31</sup>P Magnetic Resonance Spectroscopy (<sup>31</sup>P MRS) findings as well as direct measurements of phospholipid fatty acids in the brains of schizophrenic patients. Supplementation with essential fatty acids (EFA) is associated with increased membrane PUFAs and with improved clinical state.

## MEMBRANE DEFECTS IN SCHIZOPHRENIA

### Decreased Membrane Phospholipids

Early studies indicated that there were a variety of alterations in levels of phosphatidylcholine (PC), phosphatidylserine, and phosphatidylinositol (PI), and consistent decreases of phosphatidylethanolamine (PE) in RBC membranes from patients with psychoses[3]. Phospholipid abnormalities have also been found in medication-free schizophrenic patients[4], and decreases in all four key membrane phospholipids were found in fibroblasts from neuroleptic-naive schizophrenic patients[5].

<sup>31</sup>P MRS has been shown to reveal important insights into the metabolism of cell membranes. Phosphomonoesters (PMEs) are the precursors, and phosphodiester (PDEs) the breakdown products of membrane phospholipids. PME and PDE resonances reflect membrane turnover and may differ between healthy and pathological states. Phospholipids themselves constitute a large part of the broad resonance underlying the PDE and PME peaks. Pettegrew et al.[6,7] have shown significant reduction of PMEs and significantly increased levels of PDEs in the frontal cortex of neuroleptic-naive first-episode schizophrenic patients. They have proposed that changes in membrane phospholipids may be related to molecular changes that precede the onset of clinical symptoms and brain structural changes in schizophrenia[7]. Other investigators have also reported similar findings in membrane phospholipid perturbations in both acutely and chronically ill patients[8,9,10,11,12]. Direct evidence of decreased phospholipid levels comes from postmortem study of the caudate[13] of schizophrenic patients relative to normal controls, findings that may underlie an increased phospholipid breakdown observed using <sup>31</sup>P MRS.

### Decreased PUFAs

Significant reductions in plasma AA (20:4 n-6) and linoleic acid (18:2 n-6), a precursor of AA, but an increase of total n-3 fatty acids in schizophrenic patients from three geographic regions has been shown[14]. Other investigators have reported decreases in RBC membrane PUFAs in schizophrenia[15,16,17,18]. Moreover, decreases of RBC-PUFAs were not affected by haloperidol treatment[17]. Reduction of AA in skin fibroblasts has been found in first-episode schizophrenic patients[19].

Recently, a robust reduction of total PUFAs was found in schizophrenic brains, relative to control brains[13]. This is consistent with the observed reduction of membrane PE and PC. Specifically, the decrease of PUFAs was largely attributable to reductions in AA, 20:4(n-6) and, to a lesser extent its precursor, 18:2(n-6) and 20:2(n-6). A similar decrease of 20:4(n-6) was also found in the frontal cortex of schizophrenic patients[20]. These data are in accordance with findings in plasma and RBC membrane fatty acids. In light of findings of membrane defects in a variety of peripheral cell types (platelets, RBC, and fibroblasts), it has been proposed that in schizophrenia these membrane defects may be generalized in the body, thus being detectable in both extraneural tissues as well as the brain[21].

## **AA SIGNALING**

### **Phospholipid Hydrolysis and Neurotransmission**

In the brain, AA and its metabolites are considered as the intracellular second messengers. It is known that many neurotransmitters can potentiate AA release through a receptor-dependent hydrolysis of membrane phospholipids, which suggests that the receptor-mediated AA release may participate in neuronal signal transduction. Therefore, the depleted AA resulting from an increased phospholipid breakdown has been considered as a common factor that regulates prostaglandin biosynthesis, neurotransmission, and neuronal deficits in schizophrenia[22].

### ***Increased Phospholipids Degradation***

Phospholipase A<sub>2</sub> (PLA<sub>2</sub>) is a key enzyme responsible for the breakdown of membrane phospholipids. It is enriched in neuronal membranes. Increased cytoplasmic PLA<sub>2</sub> activity has been found in serum of drug-free schizophrenic patients[23,24,25]. Such increases in serum PLA<sub>2</sub> activity, however, were also found in patients with other psychiatric disorders[25], questioning the specificity of this finding to schizophrenia. Albers et al.[26] found no significant differences of serum PLA<sub>2</sub> activity between neuroleptic-naïve schizophrenics and normal controls. These discrepancies may be due to the differences in assay procedure and the heterogeneous class of extracellular PLA<sub>2</sub> [27]. Gattaz et al.[28] showed that the intracellular membrane-bound platelet PLA<sub>2</sub> activity was significantly higher in schizophrenic patients than in normal and psychiatric controls, with no significant differences between normal and psychiatric controls. It is thus unlikely that the increased platelet PLA<sub>2</sub> activity in schizophrenia results from nonspecific stressors. Furthermore, haloperidol treatment reduced platelet PLA<sub>2</sub> activity to control levels. Other neuroleptics also inhibit PLA<sub>2</sub> activity[29,30,31].

Moreover, a significant increase in spontaneous contralateral circling is seen following injection of bovine PLA<sub>2</sub> intranigrally into rats[32], which is alleviated by neuroleptics. Similar results were also obtained by Cadet and Lohr[33], who further demonstrated that intracerebral injection of PLA<sub>2</sub> can reduce dopaminergic activity. PLA<sub>2</sub> is known to inhibit dopamine-sensitive adenylate cyclase activation[34] and to reduce the [<sup>3</sup>H]spiperone binding to dopamine receptors[35].

### ***Neurotransmission***

#### ***Decreased Dopamine Transport***

Changes in membrane dynamics can affect transmembrane processes[36]. The function of the DA transporter receptor (DATR) is highly influenced by the lipid composition of membrane environment. Decreased DATR density has been found in cortical areas with high metabolic activity in

schizophrenic brains[37]. Further, both n-6 and n-3 series of PUFAs may be involved in the presynaptic receptor control of dopamine release[38]. Dopamine D<sub>2</sub> receptors have been shown to act synergistically with Ca<sup>2+</sup> stimuli to release AA from membrane phospholipids[39]. Further, dopamine D<sub>2</sub> receptors potentiate AA release via activation of cytosolic, AA-specific PLA<sub>2</sub>[40]. Thus, decreased AA can alter dopaminergic transmission.

### *Serotonin (5-HT<sub>2</sub>) Dysfunction*

There is abundant evidence that 5-HT<sub>2</sub> receptors in the brain play a regulatory role in behavior[41]. 5-HT stimulates the release of AA in hippocampal neurons through the activation of PLA<sub>2</sub> that is independent of inositol phospholipid hydrolysis[42]. Thus, 5-HT may potentially mediate some pathophysiological processes through receptor-stimulated AA or eicosanoids. We have demonstrated that drug-free schizophrenic patients exhibit reduced physiologic responsivity mediated through the platelet 5-HT<sub>2</sub> receptor complex, which can be modified by haloperidol treatment[43].

### *Impaired Glutamatergic Neurotransmission*

Activation of N-methyl-D-aspartate (NMDA) by glutamate stimulates PLA<sub>2</sub> activity to release AA, and subsequently facilitates long-term potentiation of glutamate synapses in the hippocampus, probably by a prolonged inhibition of glutamate uptake into glial cells[44]. Decreased availability of AA may lead to an impaired glutamatergic neurotransmission. A dopamine-glutamate imbalance has been postulated as one pathogenic mechanism of schizophrenia[45]. Neuroleptic drugs that block dopamine receptors may also enhance the glutamatergic neurotransmission.

### **Hyperactivity of PI Pathways**

Early studies indicated that the receptor-stimulated hydrolysis of inositol phospholipids, particularly phosphatidylinositol 4,5-bisphosphate [PI-4,5-P<sub>2</sub>], is initiated by a specific phospholipase C (PLC)[46,47]. A specific GTP-binding protein appears to be responsible for transducing the activated receptor through plasma membrane and activation of PLC. The resulting diacylglycerol (DAG) and inositol 1,4,5-triphosphate [1,4,5-IP<sub>3</sub>] lead to activation of protein kinase C (PKC) and elevation of cytosolic Ca<sup>2+</sup>, which provide molecular links between extracellular signals and intracellular events[47,48]. Thus, both DAG and IP<sub>3</sub> are second messengers that generally act in concert.

Quantitative determination of inositol phosphates provides direct evidence for PI hydrolysis by PLC in intact cells[49]. Increased turnover of platelet PI was found in both drug-treated and drug-free patients[50,51,52] but not drug-naïve patients[51]. The increased production of IP<sub>3</sub> may be due to an increase in the precursor, PI-4,5-P<sub>2</sub>, associated with a desensitization of the intracellular IP<sub>3</sub> receptor by neuroleptics[50]. On the other hand, Zilberman-Kaufman et al.[53] have reported an increased inositol-1-phosphatase in RBC of chronic schizophrenic patients. They interpreted that the increased enzyme activity might compensate physiologically for a deficiency of inositol in these patients. A trial of inositol therapy[54], however, showed no measurable psychoactive effect in chronic schizophrenic patients treated with neuroleptics.

In human platelets, DAG can be produced within 5 s of thrombin activation[55]. The newly formed DAG is either phosphorylated to phosphatidic acid (PA) by a specific DAG kinase[56] or cleaved to monoacylglycerol (MAG) by DAG lipase (see below). Both reactions may be considered as a termination for DAG intracellular signaling[57]. We have reported increased formation of DAG in thrombin-stimulated platelets of both haloperidol-treated and drug-free patients[58], consistent with the findings of Kaiya et al.[59]. Using [<sup>32</sup>P]orthophosphate as a precursor, we have previously demonstrated that thrombin-induced formation of platelet PA was substantially higher in schizophrenic patients than in normal controls[52]. Therefore, the increase in thrombin-induced

platelet DAG may be due, at least in part, to an increased PI turnover in schizophrenic patients[51,52]. Although schizophrenic patients with abnormal PI turnover appeared to have a better outcome than other patients[59], whether the second messenger (DAG) accumulation is correlated with clinical response in schizophrenia requires further investigation.

The functionality of the PI intracellular signaling has further been investigated in the postmortem human brain[60,61,62,63]. Using GTP $\gamma$ S to assess the activation of the G protein coupled with the stimulation of PLC, Jope et al.[64] have further demonstrated selective increases in PI signaling activity and G $\alpha$ o levels in postmortem brain from schizophrenic subjects. This finding is in partial agreement with the result of Wallace and Claro[63] showing a similar but not statistically significant increase in GTP $\gamma$ S-stimulated PI hydrolysis in prefrontal cortex of schizophrenic patients compared with controls. Thus, taken together with the findings in platelets, there is ample evidence of hyperactivity of the PI signaling system in schizophrenia that is markedly different from diseases with major depression and bipolar mood disorder showing a decreased activity of G protein-mediated PI hydrolysis[62,65].

## Eicosanoids

In addition to the formation of second messengers, the newly released AA from membrane phospholipids can be converted to a variety of biologically active metabolites, which are collectively referred to as eicosanoids, through the concerted reactions of cyclooxygenase (COX) and lipoxygenases. Eicosanoids are the potent messengers, which modulate neural cell function as well as involve in pathophysiological processes[66]. Since AA is the major C20 PUFAs in mammalian tissues, the prostaglandin-2 (PG<sub>2</sub>) and thromboxanes-2 (TX<sub>2</sub>) series are the predominant classes of eicosanoids. Studies involving the inhibition of COX by nonsteroidal anti-inflammatory drugs have revealed the significance of PG<sub>2</sub> in the regulation of nerve conduction, neurotransmitter release, inflammation, pain, fever, immune responses, and apoptosis.

In schizophrenia, there are reduced levels of AA in membrane phospholipids that could conceivably lead to a decreased synthesis of eicosanoids. A deficiency of prostaglandins has previously been related to schizophrenia[67]. One of the AA metabolites, PGD<sub>2</sub>, mediates vasodilatation during the inflammatory response. Therefore, the reduced AA availability may in part to explain a variety of clinical observations in schizophrenia that are usually ignored by the receptor-based etiological hypotheses[68]. For example, in schizophrenia, there appears to be a lower risk of arthritis and other inflammatory diseases[69], greater resistance to pain[70,71], and remission of psychosis during fever has been observed[67]. These effects could be secondary to a reduced eicosanoid signaling.

## Endocannabinoid System

### *Cannabinoid and Schizophrenia*

$\Delta$ 9-Tetrahydrocannabinol ( $\Delta$ 9-THC), the psychoactive ingredient from *Cannabis sativa* or marijuana[72], has been known for centuries to cause acute euphoria, altered time perception, dissociation of ideas, paranoia, motor impairment, and occasional hallucinations[73]. The behavioral effects of cannabinoids vary in humans and are mainly dose dependent. With severe intoxication, a variety of cognitive and behavioral functions including memory, attention, reaction time, concept formation, motor coordination, and perception, can also be affected. Thus, a possible relationship between THC use and the development of psychosis has been explored in the early 1970s[74,75]. In fact, many clinical symptoms from the cannabis users resemble negative symptoms in patients with acute schizophrenia[76]. Later, Chopra and Smith[77] also reported psychotic episodes following cannabis use in a group of East Indian marijuana users. Particularly, those with “schizoid” personality features exhibited full-blown schizophrenic symptoms during the period of intoxication. Sub-

sequently, Thacore and Shukla[78] have demonstrated an association of the paranoid psychosis with long-term cannabis use in 25 patients with paranoid schizophrenia. Chaudry et al.[79] and Abood and Martin[73] have further shown that moderate to severe THC intoxication closely mimics many of the positive and negative symptoms of schizophrenia. However, whether cannabis psychosis is a distinct clinical entity remains unclear[80].

Although the role of cannabis in the development of schizophrenia is unclear, the drug may modify the course of an already established illness[80]. For example, cannabis can affect the severity of schizophrenic symptoms[81], increase relapse rates[82], and decrease the efficacy of antipsychotic drugs[83]. In a longitudinal study of 45,570 subjects with 15 years follow-up, Andreasson et al.[84,85] have demonstrated that individuals with cannabis consumption have increased risk up to sixfold of developing schizophrenia as compared to normals or other drug users.

On the other hand, there were no differences in psychotic symptoms between schizophrenic patients with and without cannabis abuse. However, decreased negative symptoms were observed in cannabis users[86,87].

### **Tetrahydrocannabinol (THC) Ligands**

In 1988, Devane et al.[88] first characterized cannabinoid receptor in rat brain membranes. Recently, two endogenous THC ligands, anandamide[89] and 2-arachidonoylglycerol (2-AG)[90,91], have been discovered in the brain. Both anandamide and 2-AG are derivatives of AA. Anandamide is synthesized by the “transacylase-phosphodiesterase pathway”[92], which transfers the sn-1 linked acyl group of a glycerophospholipid to the ethanolamine group of PE. On the other hand, 2-AG is formed through the PLC-mediated degradation of PI as well as other membrane phospholipids. The resulting DAGs are hydrolyzed by sn-1-DAG lipase to produce 2-MAG, including 2-AG.

Because AA is primarily esterified at the sn-2 position of glycerophospholipids, 2-AG is often a major component of cellular MAG. On the other hand, NAEs that derive their fatty acids from the sn-1 position contain only trace amounts of anandamide (20:4 NAE) in virtually all mammalian cells and tissues, as well as in plasma. In brain, however, 2-AG is present in amounts 170 times greater than anandamide[91].

Given the localization of endogenous cannabinoid receptor (CB<sub>1</sub>) system in brain areas (i.e., cortical and limbic structures) known to be implicated in schizophrenic brain pathology[93,94], it is plausible that dysfunction of CB<sub>1</sub> system with endogenous ligands be associated with the pathophysiology of schizophrenia. Moreover, there is a close interaction between CB<sub>1</sub> and dopaminergic systems. Cannabinoid agonists such as THC and the endogenous ligands, anandamide and 2-AG, can modulate the dopaminergic system[95,96,97]. Our lab[2] as well as others[16,18,20] have reported abnormalities in membrane AA from patients with schizophrenia. Since AA is the precursor of anandamide and 2-AG, it is possible that there exists a dysfunction of CB<sub>1</sub> system in schizophrenia.

Recently, Berdyshev et al.[98] have shown that production of 2-AG is markedly elevated during platelet activation. Taken together from the above observations, it is likely that an increased 2-AG resulting from the hyperactivity of PI signaling system and DAG second messenger formation enhance the activation of cannabinoid receptor system in schizophrenia. This hypothesis is in agreement with the view[99] that the ability of platelets to generate 2-AG and release it into the circulation may affect cannabinoid receptors in the brain.

## **CLINICAL RELEVANCE**

### **Clinical Correlates**

Low levels of RBC AA have been associated with prominent negative symptoms[16] and persistent positive symptoms[100]. In drug-free chronic schizophrenic patients, we found linoleic acid levels

were inversely correlated with psychosis severity, suggesting the possibility of a defect in the conversion of linoleic acid to AA. Although these studies were conducted in chronic schizophrenic patients, no effects of long-term typical neuroleptics on AA levels were observed. Reduced incorporation of AA has been found in schizophreniform and untreated schizophrenic patients[101]. Recently, we have also demonstrated a decreased level of PUFAs in RBC membranes of first-episode neuroleptic-naïve schizophrenic patients[102], suggesting membrane pathology is present also early in the course of illness. Thus, a specific membrane defect may be associated with poor outcome (prominent negative and persistent positive symptoms), and may be present early in illness.

### **Tardive Dyskinesia (TD)**

Approximately 20% of patients receiving neuroleptics long term develop TD, often in those patients who exhibit the deficit syndrome. Vaddadi et al.[15] found that psychiatric patients (primarily schizophrenics) with TD had significantly lower RBC PUFA of both n-6 and n-3 series. The reduction of PUFA progressed as the severity of the TD worsened. These PUFA abnormalities were thought to be due to dietary factors, drug therapy, and hospitalization status[103]. Low plasma AA levels may also increase the risk for dyskinesia in the general elderly population. Nilsson et al.[104] found in 446 older Swedish men that the rate of dyskinesia was 15.1%, with a robust association with low AA. Zubenko and Cohen[105] have shown that platelet membrane fluidity, a direct measure of membrane function, is altered in patients with TD.

### **Niacin-Induced Flushing**

Facial flushing is induced by 200 mg of oral niacin in about an hour in the majority of normal and depressed subjects[106]. Schizophrenic patients with low levels of AA fail to flush in response to oral niacin[107]. Some patients with schizophrenia, particularly those with the negative or deficit syndrome, fail to flush facially in response to niacin[106,108,109]. Niacin flushing is dependent on the release of prostaglandin E<sub>1</sub> from 18:3(n-6)[108] and of prostaglandin D<sub>2</sub> from AA[110]. It is known that PGD<sub>2</sub> is involved in the vasodilation during the inflammatory response. Since PGD<sub>2</sub> is synthesized from the AA released from membrane phospholipids, the reduced niacin-induced flushing may be due to reduced membrane phospholipid AA. It is conceivable that endocannabinoid overproduction may downregulate prostaglandin biosynthesis, since both pathways share the same precursor, AA.

### **Later Onset of Illness in Female Patients**

Males are more likely to develop schizophrenia at an earlier age, whereas females tend to have the onset of illness[111,112,113]. Females may have a lower requirement than males for EFA, possibly because of the presence of estrogen[114,115], and thus might be expected to retain membrane AA in early life better than males. Such an advantage, however, would disappear after menopause[21].

### **Other Mental Disorders**

Membrane phospholipid abnormalities have been observed in dyslexia and attention deficit hyperactivity disorder (ADHD)[116,117]. Clinical features common to schizophrenia and these developmental disorders include language system and attention deficits[118,119]. Thus, PUFAs membrane deficits may explain many biological, physiological, and clinical consequences observed in schizophrenia[68].

## **THERAPEUTIC EFFICACY (AA, AN INDEX OF THERAPEUTIC EFFECT?)**

The mainstay of treatment of schizophrenia is an antipsychotic agent, primarily the typical and atypical neuroleptics. However, the response to current treatments is variable and far from acceptable, with only 60% of schizophrenic patients responding favorably. Treatment nonresponders frequently have prominent cognitive deficits and negative symptoms. Thus, any feasible method that can mitigate the persistent positive and negative symptoms, as well as the cognitive deficits can improve outcome.

### **PUFA Supplementation: Correlation between Clinical State and RBC AA**

Investigating EFA metabolism has proved fruitful for generating and testing novel etiologic hypotheses and new therapeutic agents for schizophrenia[120]. The early studies of PUFA supplementation were aimed at TD without significant success[121,122,123,124].

However, dietary supplementation with eicosapentaenoic acid (EPA), a precursor of docosahexanoic acid (DHA), has shown promising results in decreasing some of the clinical symptoms of schizophrenia[18,125,126,127], as well as cognitive impairments associated with dyslexia and ADHD[116,117]. There were no treatment-related side effects or adverse biochemical or hematological effects[128]. In a multicenter study with EPA treatment, Peet and Horrobin[128] have shown that patients on 2 g/day not only showed significant reduction of plasma triglycerides levels which had been elevated by clozapine, but also clinically improved. In addition, there was a positive correlation between clinical improvement and rise in RBC AA concentration.

### **Atypical Antipsychotic Treatment: Ability of Apolipoprotein D to Bind AA**

Clozapine, a widely used atypical antipsychotic drug, has been shown to be effective and relatively well tolerated in acute and long-term treatment of patients with schizophrenia, especially those who have not responded to conventional pharmacotherapies[129]. In contrast to typical neuroleptics, the dopamine D<sub>2</sub> receptor antagonists, clozapine exhibits an expanded spectrum of affinity for other neurotransmitter receptors, including 5-HT<sub>2</sub>, histamine, muscarinic and adrenergic receptors[130]. However, the improved clinical efficacy of clozapine may not be attributed exclusively to its drug-blocking profile.

In order to understand the molecular mechanisms of clozapine's potentially unique actions, a PCR-based differential gene expression method, TOGA (Total Gene Expression Analysis) was used to identify genes whose expression may be altered by clozapine administration[131]. Following screening procedures, a regulation of apolipoprotein D (apoD) has been unveiled in the mouse brain resulting from clozapine treatment. Increases in apoD expression were detected in white matter regions, including corpus callosum, internal capsule and optic tract, and gray matter regions, including the striatum and globus pallidus[131]. These results implicate apoD in the mechanisms of action of clozapine.

*In vitro*, apoD has been shown to bind and transport ligands including AA, cholesterol, a human axillary odorant, heme-related molecules and steroid hormones, such as progesterone and pregnenolone[132,133,134,135,136,137]. Despite the ability of apoD to bind these small molecules, the physiological ligand(s) has yet to be identified definitively and it is possible that apoD has multiple, tissue-specific physiological ligands that may function differently under normal and pathological circumstances. Interestingly, the ability of apoD to bind AA implicates it in pathways associated with membrane phospholipid signal transduction and metabolism. Clozapine has been shown to increase AA and DHA levels in RBC phospholipids from schizophrenic patients[107,138]. It is likely that the elevated apoD levels such as those caused by clozapine may be linked with the observed clozapine-induced increase in AA, and possibly be beneficial for patients.



## Mood Stabilizers: Inhibition of AA-Specific Cytosolic PLA<sub>2</sub> by Lithium or Valproic Acid

Although lithium and valproic acid have been shown effectively in treating both phases of bipolar disorders, it is not clear whether a common biochemical pathway underlie their action. Because of lithium's ability to inhibit inositol-1-phosphatase, the sensitivity of receptor systems that utilize PI may be altered by prolonged exposure to lithium[46,139]. Thus, the therapeutic actions of lithium have been targeted toward those neuronal systems in which the receptor-mediated PI turnover is most active[140,141,142]. Changes in the second messengers may result in prolonged effector stimulation that could underlie mania. Similarly, excessive receptor desensitization may lead to depression. However, the chronic lithium treatment at relevant clinical doses only exhibit modest or no changes in PI turnover[143]. In addition, other membrane phospholipids were also altered in rat brain following chronic lithium treatment[144].

Following intravenous infusion of radiolabeled palmitic acid and AA in awake rats treated chronically with lithium, Chang et al.[145] have demonstrated decreased turnover rate of AA second messenger in brain phospholipids by up to 80%. In contrast, lithium had a minimal effect on turnover of palmitic acid. Decreased AA turnover was associated with a down-regulation of gene expression and protein levels of AA-specific cytosolic phospholipase A<sub>2</sub> (cPLA<sub>2</sub>), but not with the intracellular PLA<sub>2</sub>[146]. Similarly, valproic acid had the same effect on AA turnover, although it did not alter the cPLA<sub>2</sub> protein levels[147]. Taken together, both lithium and valproic acid have the same therapeutic action in reducing brain turnover of AA, probably via a different mechanism.

## CONCLUSION

There is accumulating evidence of membrane fatty acid compositional deficits in schizophrenia. These deficits have been found in peripheral tissues and the brain, in both neuroleptic-naïve and treated patients. The membrane fatty acid deficits are specific, primarily reductions in the n-3 and n-6 classes. Although much of the attention by early investigators has on n-3 fatty acids, increasing attention is being paid to the potentially important role that AA may play in the pathophysiology of schizophrenia. Recent clinical trials suggest that AA may be an index of therapeutic, and possibly pharmacological, action. AA has a key role in many physiological mechanisms that mediate signal transduction. Thus, future studies should clarify the specific role that AA has in the development, illness presentation and treatment of schizophrenia and related disorders.

## ACKNOWLEDGEMENTS

This study was supported in part by the Office of Research and Development (Merit Review, JKY), Department of Veterans Affairs, the Highland Drive VA Pittsburgh Healthcare System, and research grants from the National Institute of Mental Health (MH43742 and MH58141).

## REFERENCES

1. Lieberman, J.A. and Koreen, A.R. (1993) Neurochemistry and neuroendocrinology of schizophrenia: a selective review. *Schizophr. Bull.* **19**, 371–429.
2. Yao, J.K. (1999) Red blood cell and platelet fatty acid metabolism in schizophrenia. In *Phospholipid Spectrum Disorder in Psychiatry*. Peet, M., Glen, I., and Horrobin, D.F., Eds. Marius Press, Lancashire, U.K. pp. 57–71.
3. Rotrosen, J. and Wolkin, A. (1987) Phospholipid and prostaglandin hypotheses of schizophrenia. In *Psychopharmacology, The Third Generation on Progress*. Meltzer, N.Y., Ed. Raven Press, New York. pp. 759–764.
4. Keshaven, M.S., Mallinger, A.G., Pettegrew, J.W., and Dippold, C. (1993) Erythrocyte membrane phospholipids in psychotic patients. *Psychiatr. Res.* **49**, 89–95.

5. Mahadik, S.P., Mukherjee, S., Correnti, E., Kelkar, H.S., Wakade, C.G., Costa, R.M., and Scheffer, R. (1994) Distribution of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug-naïve patients at the onset of psychosis. *Schizophr. Res.* **13**, 239–247.
6. Pettegrew, J.W., Keshavan, M.S., Panchalingam, K., Strychor, S., Kaplan, D.B., Tretta, M.G., and Allen, M. (1991) Alterations in brain high energy phosphate and membrane phospholipid metabolism in first episode drug naïve schizophrenics. *Arch. Gen. Psychiatry* **48**, 563–568.
7. Pettegrew, J.W., Keshavan, M.S., and Minshew, N.J. (1993) <sup>31</sup>P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia. *Schizophr. Bull.* **19**, 335–353.
8. Deicken, R.F., Merrin, E., Calabrese, G., Dillon, W., Weiner, M.W., and Fein, G. (1993) <sup>31</sup>P Phosphorus MRSI in the frontal and parietal lobes in schizophrenia. *Biol. Psychiatry* **33**, 46A.
9. Fukazako, H., Takeuchi, K., Fujimoto, T., Fukuzako, T., Hokazono, Y., Hirakawa, K., Ueyama, K., and Matsumoto, K. (1992) <sup>31</sup>P magnetic resonance spectroscopy of schizophrenic patients with neuroleptic resistant positive and negative symptoms. *Biol. Psychiatry* **31**(S), 204A–205A.
10. Fukuzako, H., Fukuzako, T., Takeuchi, K., Ohbo, Y., Ueyama, K., Takigawa, M., and Fujimoto, T. (1996) Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in temporal lobe and positive symptoms. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **20**, 629–640.
11. Stanley, J.A., Williamson, P.C., Drost D.J., et al. (1993) The study of schizophrenia via in vivo <sup>31</sup>P and <sup>1</sup>H MRS. *Schizophr. Res.* **9**, 210.
12. Williamson, P., Drost, D., Stanley, J., Carr T., et al. (1991) Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. [Letter] *Arch. Gen. Psychiatry* **48**, 578.
13. Yao, J.K., Leonard, S., and Reddy, R. (2000) Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. *Schizophr. Res.* **42**, 7–17.
14. Horrobin, D.F., Manku, M.S., Morse-Fisher, N., Vaddadi, K.S., Courtney, P., Glen, A.I.M., Glen, E., Spellman, M., and Bates, C. (1989) Essential fatty acid in plasma phospholipids in schizophrenics. *Biol. Psychiatry* **25**, 562–568.
15. Vaddadi, K.S., Courtney, P., Gilleard, C.J., Manku, M.S., and Horrobin, D.F. (1989) A double blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. *Psychiatr. Res.* **27**, 313–323.
16. Glen, A.I.M., Glen, E.M.T., Horrobin, D.F., et al. (1994) A red cell membrane abnormality in a sub-group of schizophrenic patients: evidence for two diseases. *Schizophr. Res.* **12**, 53–61.
17. Yao, J.K., van Kammen, D.P., and Welker, J.A. (1994) Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. *Schizophr. Res.* **13**, 217–226.
18. Peet, M., Laugharne, J.D.E., Mellor, J., and Ramchand, C.N. (1996) Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. *Prostagland. Leukotr. Essent. Fatty Acids* **55**, 71–75.
19. Mahadik, S.P., Mukherjee, S., Horrobin, D.F., Jenkins, K., Correnti, E.E., and Scheffer, R.E. (1996) Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. *Psychiatr. Res.* **63**, 133–142.
20. Horrobin, D.F., Manku, M.S., Hillman, H., and Glen, A.I.M. (1991) Fatty acid levels in the brains of schizophrenics and normal controls. *Biol. Psychiatry* **30**, 795–805.
21. Horrobin, D.F. (1996) Schizophrenia as a membrane lipid disorder which is expressed throughout the body. *Prostagland. Leukotr. Essent. Fatty Acids* **55**, 3–8.
22. Peet, M., Laugharne, J.D.E., Horrobin, D.F., and Reynolds, G.P. (1994) Arachidonic acid: a common link in the biology of schizophrenia? *Arch. Gen. Psychiatry* **51**, 665–666.
23. Gattaz, W.F., Kollisch, M., Thuren, T., Virtanen, J.A., and Kinnunen, P.K.J. (1987) Increased plasma phospholipase-A<sub>2</sub> activity in schizophrenic patients: reduction after neuroleptic therapy. *Biol. Psychiatry* **22**, 421–426.
24. Gattaz, W.F. (1992) Phospholipase A<sub>2</sub> in schizophrenia. *Biol. Psychiatry* **31**, 209–216.
25. Noponen, M., Sanfilippo, M., Samanich, K., Ryer, H., K, G., Angrist, B., Wolkin, A., Duncan E., and Rotrosen J. (1993) Elevated PLA<sub>2</sub> activity in schizophrenics and other psychiatric patients. *Biol. Psychiatry* **34**, 641–649.
26. Albers, M., Meurer, H., Marki, F., and Klotz, J. (1993) Phospholipase A<sub>2</sub> activity in serum of neuroleptic-naïve psychiatric inpatients. *Pharmacopsychiatry* **26**, 4–98.
27. Ross, B.M., Hudson, C., Erlich, J., Warsh, J.J., and Kish, S.J. (1997) Increased phospholipid breakdown in schizophrenia. *Arch. Gen. Psychiatry* **54**, 487–494.
28. Gattaz, W.F., Schmitt, A., and Maras, A. (1995) Increased platelet phospholipase A<sub>2</sub> activity in schizophrenia. *Schizophr. Res.* **16**, 1–6.
29. Schroder, T., Lempinen, M., Nordling, S., and Kinnunen, P.K.J. (1981) Chlorpromazine treatment of experimental acute fulminant pancreatitis in pigs. *Eur. Surg. Res.* **13**, 143–151.
30. Aarsman, A.J., Roosenboom, C.F.P., van Geffen, G.E.W., and van den Bosch, H. (1985) Some aspects of rat platelet and serum phospholipase A<sub>2</sub> activities. *Biochim. Biophys. Acta* **837**, 88–95.
31. Taniguchi, K., Urakami, M., and Takanaka, K. (1988) Effects of various drugs on superoxide generation, arachidonic acid release and phospholipase A<sub>2</sub> in polymorphonuclear leukocytes. *Jpn. J. Pharmacol.* **46**, 275–284.
32. Gattaz, W.F., Stendle, A., Maras, A., and Brunner, J. (1994) Accelerated breakdown of platelet membrane phospholipids in schizophrenia. *Schizophr. Res.* **11**, 122.

33. Cadet, J.L. and Lohr, J.B. (1989) Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. *Ann. N. Y. Acad. Sci.* **570**, 176–185.
34. Anand-Srivastava, M.B. and Johnson, R.A. (1981) Role of phospholipids in coupling of adenosine and dopamine receptors to striatal adenylate cyclase. *J. Neurochem.* **36**, 819–828.
35. Oliverira, C.R., Duarte, E.P., and Carvalho, A.P. (1984) Effect of phospholipase digestion and lysophosphatidylcholine on dopamine receptor binding. *J. Neurochem.* **43**, 455–465.
36. Hitri, A., Hurd, Y.L., Wyatt, R.J., and Deutsch, S.I. (1994) Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance. *Clin. Neuropharmacol.* **17**, 1–22.
37. Hitri, A., Casanova, M.F., Kleinman, J.E., Weinberger, D.R., and Wyatt, R.J. (1995) Age-related changes in [<sup>3</sup>H]GBR 12935 binding site density in the prefrontal cortex of controls and schizophrenics. *Biol. Psychiatry* **37**, 175–182.
38. Davidson, B., Kurstjens, N.P., Patton, J., and Cantrill, R.C. (1988) Essential fatty acids modulate apomorphine activity at receptors in cat caudate slices. *Eur. J. Pharmacol.* **149**, 317–322.
39. Piomelli, D. (1993) Eicosanoids in synaptic transmission. *Crit. Rev. Neurobiol.* **8**, 65–83.
40. Vial, D. and Piomelli, D. (1995) Dopamine D2 receptors potentiate arachidonate release via activation of cytosolic, arachidonate-specific phospholipase A2. *J. Neurochem.* **64**, 2765–2772.
41. Leysen, J.E. and Pauwels, P.J. (1990) 5-HT<sub>2</sub> receptors, roles and regulation. *Ann. N.Y. Acad. Sci.* **600**, 183–191.
42. Felder, C.C., Kanterman, R.Y., Ma, A.L., and Axelrod, J. (1990) Serotonin stimulates phospholipase A<sub>2</sub> and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis. *Proc. Natl. Acad. Sci. U. S. A.* **87**, 2187–2191.
43. Yao, J.K., van Kammen, D.P., Moss, H.B., and Sokulski, D.E. (1996) Decreased serotonergic responsivity in platelets of drug-free patients with schizophrenia. *Psychiatry Res.* **63**, 123–132.
44. Barbour, B., Szatkowski, M., Ingledew, N., and Attwell, D. (1989) Arachidonic induces a prolonged inhibition of glutamate uptake into glial cells. *Nature* **342**, 918–920.
45. Carlsson, M. and Carlsson, A. (1990) Schizophrenia: a subcortical neurotransmitter imbalance syndrome? *Schizophr. Bull.* **16**, 425–432.
46. Berridge, M.J., Downes, C.P., and Hanley, M.R. (1984) Lithium amplifies agonist-dependent transduction. *Nature* **312**, 315.
47. Nishizuka, Y. (1992) Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. *Science* **258**, 607–614.
48. Kishimoto, A., Takai, Y., Mori, T., Kikkawa, U., and Nishizuka, Y. (1980) Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. *J. Biol. Chem.* **255**, 2273–2276.
49. Siess, W. (1989) Molecular mechanism of platelet activation. *Physiol. Rev.* **69**, 58–141.
50. Das, I., Essali, M.A., deBellerocche, J., and Hirsch, S.R. (1992) Inositol phospholipid turnover in platelet of schizophrenic patients. *Prostagland. Leukotr. Essent. Fatty Acids* **46**, 65–66.
51. Essali, M.A., Das, I., Bellerocche, J., and Hirsch, S.R. (1990) The platelet phospho-inositide system in schizophrenia: the effects of neuroleptic treatment. *Biol. Psychiatry* **28**, 475–487.
52. Yao, J.K., Yasaei, P., and van Kammen, D.P. (1992) Increased turnover of platelet phosphatidylinositol in schizophrenia. *Prostagland. Leukotr. Essent. Fatty Acids* **46**, 39–46.
53. Zilberman-Kaufman, M., Agam, G., Moscovitz, L., Livne, A.A., and Belmaker, R.H. (1992) Elevated inositol monophosphatase activity in schizophrenic patients. *Clin. Chem. Acta* **209**, 89–93.
54. Levine, J., Umansky, R., Ezrielev, G., and Belmaker, R.H. (1993) Lack of effect of inositol treatment in chronic schizophrenia. *Biol. Psychiatry* **33**, 673–675.
55. Rittenhouse-Simmons, S. (1979) Production of diglyceride from phosphatidylinositol in activated human platelets. *Clin. Invest.* **63**, 580–587.
56. Lapetina, E.G. and Hawthorne, J.N. (1971) The diglyceride kinase of rat cerebral cortex. *Biochemistry* **122**, 171–179.
57. Fisher, S.K. and Agranoff, B.W. (1999) Phosphoinositides. In *Basic Neurochemistry: Molecular, Cellular, and Medical Aspects*, 6<sup>th</sup> Ed. Siegel, G.J., Agranoff, B.W., Albers, W.R., Fisher, S.K., and Uhler, M.D., Eds. Lippincott-Raven Press, New York. pp. 415–431.
58. Yao, J.K., van Kammen, D.P., and Gurklis, J. (1996) Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia. *Psychiat. Res.* **60**, 11–21.
59. Kaiya, H., Nishida, A., Imai, A., Nakashima, S., and Nozawa, Y. (1989) Accumulation of diacylglycerol in platelet phosphoinositide turnover in schizophrenia: a biological marker of good prognosis? *Biol. Psychiatry* **26**, 669–676.
60. Jope, R.S., Song, L., and Powers, R. (1994) Agonist-induced, GTP-Dependent phosphoinositide hydrolysis in postmortem human brain membranes. *J. Neurochem.* **62**, 180–186.
61. O'Neill, C., Fowler, C.J., Wiehager, B., Alafuzuff, I., and Winblad, B. (1991) Assay of a phosphatidylinositol bisphosphate phospholipase C activity in postmortem human brain. *Brain Res.* **543**, 307–314.
62. Pacheco, M.A. and Jope, R.S. (1996) Phosphoinositide signaling in human brain. *Prog. Neurobiol.* **50**, 255–273.
63. Wallace, M.A. and Claro, E. (1993) Transmembrane signalling through phospholipase C in human cortical membranes. *Neurochem. Res.* **18**, 139–145.

64. Jope, R.S., Song, L., Grimes, C.A., Pacheco, M.A., Dilley, G.E., Li, X., Meltzer, H.Y., Overholser, J.C., and Stockmeier, C.A. (1998) Selective increases in phosphoinositide signaling activity and G protein levels in postmortem brain from subjects with schizophrenia or alcohol dependence. *J. Neurochem.* **70**, 763–771.
65. Jope, R.S., Song, L., Li, P.P., Young, L.T., Kish, S.J., Pacheco, M.A., and Warsh, J.J. (1996) The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. *J. Neurochem.* **66**, 2402–2409.
66. Bazan, N.G. (1999) Eicosanoids, platelet-activating factor and inflammation. In *Basic Neurochemistry: Molecular, Cellular, and Medical Aspects*, 6<sup>th</sup> Ed. Siegel, G. J., Agranoff, B.W., Albers, W.R., Fisher, S.K., and Uhler, M.D., Eds. Lippincott-Raven Press, New York. pp. 731–741.
67. Horrobin, D.F. (1977) Schizophrenia as a prostaglandin deficiency disease. *Lancet* **1**, 936–937.
68. Horrobin, D.F. (1998) The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. *Schizophr. Res.* **30**, 193–208.
69. Eaton, W.W., Hayward, C., and Ram, R. (1992) Schizophrenia and rheumatoid arthritis: a review. *Schizophr. Res.* **6**, 181–192.
70. Horrobin, D.F., Ally, A.I., Karmali, R.A., Karmazyn, M., Manku, M.S., and Morgan, R.O. (1978) Prostaglandins and schizophrenia: further discussion of the evidence. *Psychol. Med.* **8**, 43–48.
71. Davis, G.C., Buchsbaum, M.S., van Kammen, D.P., and Bunney, W.E. (1979) Analgesia to pain stimuli in schizophrenics and its reversal by naltrexone. *Psychiatry Res.* **1**, 61–69.
72. Gaoni, Y. and Mechoulam, R. (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. *J. Am. Chem. Soc.* **86**, 1646–1647.
73. Abood, M.E. and Martin, B.R. (1992) Neurobiology of marijuana use. *Trends Pharmaceut. Sci.* **13**, 202–207.
74. Spencer, D.J. (1970) Cannabis induced psychosis. *Br. J. Addiction* **65**, 369–372.
75. Halikas, J.A., Goodwin, D.W., and Guze, S.B. (1972) Marijuana use and psychiatric illness. *Arch. Gen. Psychiatry* **27**, 162–165.
76. Kupfer, D.J., Detre, T., Koral, J., and Fajans, P. (1973) A comment on the “amotivational syndrome” in marijuana smokers. *Am. J. Psychiatry* **130**, 1319–1321.
77. Chopra, G.S. and Smith, J. W. (1974). Psychotic reactions following cannabis use in East Indians. *Arch. Gen. Psychiatry* **30**, 24–27.
78. Thacore, V.R. and Shukla, S.R. (1976) Cannabis psychosis and paranoid schizophrenia. *Arch. Gen. Psychiatry* **33**, 383–386.
79. Chaudry, H.R., Moss, H.B., Bashir, A., and Suliman, T. (1991) Cannabis psychosis following bhang ingestion. *Br. J. Addiction* **86**, 1075–1081.
80. Thomas, H. (1993) Psychiatric symptoms in cannabis users. *Br. J. Psychiatry* **163**, 141–149.
81. Negrete, J.C., Knapp, W.P., Douglas, D.E., and Smith, B.W. (1986) Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. *Psychol. Med.* **16**, 515–520.
82. Linszen, D.H., Dingemans, P.M., and Lenior, M.A. (1994) Cannabis abuse and the course of recent-onset schizophrenic disorders. *Arch. Gen. Psychiatry* **51**, 273–279.
83. Knudsen, P. and Vilmar, T. (1984) Cannabis and neuroleptic agents in schizophrenia. *Acta Psychiatr. Scand.* **69**, 162–174.
84. Andreasson, S., Allebeck, P., Engstrom, A., and Rydberg, U. (1987) Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. *Lancet* **2**, 1483–1485.
85. Andreasson, S., Allebeck, P., and Rydberg, U. (1989) Schizophrenia in users and non-users of cannabis: a longitudinal study in Stockholm county. *Acta Psychiatr. Scand.* **79**, 505–510.
86. Rottanburgh, D., Robins, A.H., Ben-Arie, O., Teggin, A., and Elk, R. (1982) Cannabis-associated psychosis with hypomanic features. *Lancet* **2**, 1364–1366.
87. Peralta, V. and Cuesta, M.J. (1992) Influence of cannabis abuse on schizophrenic psychopathology. *Acta Psychiatr. Scand.* **85**, 127–130.
88. Devane, W.A., Dysarz, III, F.A., Johnson, M.R., Melvin, L.S., and Howlett, A.C. (1988) Determination and characterization of a cannabinoids receptor in rat brain. *Mol. Pharmacol.* **34**, 605–613.
89. Devane, W.A., Hanus, L., Breur, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* **258**, 1946–1949.
90. Sugiura, T., Kodaka, T., Kondo, S., Nakane, S., Kondo, H., Waku, K., Ishima, Y., Watanabe, K., and Yamamoto, L. (1997) Is the cannabinoid CB1 receptor a 2-arachidononylglycerol receptor? Structural requirements for triggering a Ca<sup>2+</sup> transient in NG108-15 cells. *J. Biochem. (Tokyo)* **122**, 890–895.
91. Stella, N., Schweitzer, P., and Piomelli, D. (1997) A second endogenous cannabinoid that modulates long-term potentiation. *Nature* **388**, 773–778.
92. Schmid, H.H.O. (2000) Pathways and mechanisms of N-acyl ethanolamine biosynthesis: can anandamide be generated selectively? *Chem. Phys. Lipids* **108**, 71–88.
93. Herkenham, M., Lynn, A.B., Little, M.D., Johnson, R.M., Melvin, L.S., De Costa, B.R., and Rice, K.C. (1990) Cannabinoid receptor localization in brain. *Proc. Natl. Acad. Sci. U. S. A.* **87**, 1932–1936.

94. Herkenham, M., Lynn, A.B., Johnson, M.R., Melvin, L.S., Decosta, B.R., and Rice, K.C. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative *in vitro* autoradiographic study. *J. Neurosci.* **11**, 563–583.
95. French, E.D. (1997) Delta-9-tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. *Neurosci. Lett.* **226**, 159–162.
96. Sanudo-Pena, M.C., Patrick, S.L., Patrick, R.L., and Walker, M. (1996) Effects of intranigral cannabinoids on rotational behavior in rats: interactions with the dopaminergic system. *Neurosci. Lett.* **206**, 21–24.
97. Gardner, E.L. and Lowinson, J.H. (1991) Marijuana's interaction with brain reward systems: update 1991. *Pharmacol. Biochem. Behav.* **40**, 571–580.
98. Berdyshev, E.V., Schmid, P.C., Krebsbach, R.J., and Schmid, H.H.O. (2001) Activation of PAF receptors results in enhanced synthesis of 2-arachidonylglycerol (2-AG) in immune cells. *FASEB J.* **15**, 2171–2178.
99. Pryor, S.R. (2000) Is platelet release of 2-arachidonoyl-glycerol a mediator of cognitive deficits? An endocannabinoid theory of schizophrenia and arousal. *Med. Hypotheses* **55**, 494–501.
100. Peet, M., Laugharne, J.D.E., Rangarajan, N., Horrobin, D.F., and Reynolds, G. (1995) Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. *J. Psychiatr. Res.* **29**, 227–232.
101. Demisch, L., Heinz, K., Gerbaldo, H., and Kirsten, R. (1992) Increased concentrations of phosphatidylinositol and decreased esterification of arachidonic acid into phospholipids in platelets from patients with schizoaffective disorders or atypical phasic psychoses. *Prostagland. Leukotr. Essent. Fatty Acids* **46**, 47–52.
102. Reddy, R.D., Yao, J.K., Zeigler, M., and Keshavan, M.S. (1999) Essential fatty acids and outcome in first-episode schizophrenia. *Schizophr. Res.* **36**, 108.
103. Vaddadi, K.S. (1996) Dyskinesias and their treatment with essential fatty acids: a review. *Prostagland. Leukotr. Essent. Fatty Acids* **55**, 89–94.
104. Nilsson, A., Horrobin, D.F., Rosengren, A., Waller, L., Adlerberth, A., and Wilhelmsen, L. (1996) Essential fatty acids and abnormal involuntary movements in the general male population: a study of men born in 1933. *Prostagland. Leukotr. Essent. Fatty Acids* **55**, 83–87.
105. Zubenko, G.S. and Cohen, B.M. (1986) A cell membrane correlate of tardive dyskinesia in patients treated with phenothiazines. *Psychopharmacology* **88**, 230–236.
106. Rybakowski, J. and Weterle, R. (1991) Niacin test in schizophrenia and affective illness. *Biol. Psychiatry* **29**, 834–836.
107. Glen, A.I.M., Cooper, S.J., Rybakowski, J., Vaddadi, K., Brayshaw, N., and Horrobin, D.F. (1996) Membrane fatty acids, niacin flushing and clinical parameters. *Prostagland. Leukotr. Essent. Fatty Acids* **55**, 9–15.
108. Horrobin, D.F. (1980) Niacin flushing, prostaglandin E and evening primrose oil. A possible objective test for monitoring therapy in schizophrenia. *J. Orthomol. Psychiat.* **9**, 33–34.
109. Hudson, C.J., Lin, A., Cogan, S., and Warsh, J.J. (1995) Clinical detection of altered prostaglandin function in a schizophrenia sub-type. *Schizophr. Res.* **15**, 60.
110. Morrow, J.D., Awad, J.A., Oates, J.A., and Roberts, L.J. (1992) Identification of skin as a major site of prostaglandin D<sub>2</sub> release following oral administration of niacin in humans. *J. Invest. Dermatol.* **98**, 812–815.
111. McNeil, T.F., Cantor-Graae, E., Nordstrom, L.G., and Rosenlund, T. (1993) Head circumference in 'preschizophrenic' and control neonates. *Br. J. Psychiatry* **162**, 517–523.
112. Rifkin, L., Jones, P., and Murray, R.M. (1993) Low birth weight and poor premorbid childhood function predict cognitive impairment in schizophrenia. *Schizophr. Res.* **9**, 138–139.
113. Wahl, O.F. and Hunter, J. (1992) Are gender effects being neglected in schizophrenia research. *Schizophr. Bull.* **18**, 313–317.
114. Pudlakiewicz, C., Seufert, J., and Holman, R.T. (1968) Requirements of the female rat for linoleic and linolenic acids. *J. Nutr.* **64**, 138–147.
115. Huang, Y.S., Horrobin, D.F., Watanabe, Y., Barlett, M.E., and Simmons, V.A. (1990) Effects of dietary linoleic acid on growth and liver phospholipid fatty acid composition in intact and gonadectomized rats. *Biochem. Arch.* **6**, 47–54.
116. Richardson, A.J., Easton, T., McDaid, A.M., Hall, J.A., Montgomery, P., Clisby, C., and Puri, B.K. (1999) Essential fatty acids in dyslexia: theory, evidence and clinical trails. In *Phospholipid Spectrum Disorder in Psychiatry*. Peet, M., Glen, I., and Horrobin, D.F., Eds. Marius Press, Lancashire, U.K. pp. 225–241.
117. Stordy, B. (1999) Long-chain fatty acids in the management of dyslexia and dyspraxia. In *Phospholipid Spectrum Disorder in Psychiatry*. Peet, M., Glen, I., and Horrobin, D.F., Eds. Marius Press, Lancashire, U.K. pp. 251–260.
118. Maher, B.A. (1991) Language and schizophrenia. In *Handbook of Schizophrenia: Neuropsychology, Psychophysiology, and Information Processing*. Vol. 5. Steinhauer S.R., Gruzelier, J.H., Zubin, J., Eds. Elsevier, Amsterdam. pp. 437–464.
119. Nuechterlein, K.H. (1991) Vigilance in schizophrenia and related disorders. In *Handbook of Schizophrenia: Neuropsychology, Psychophysiology, and Information Processing*. Vol. 5. Steinhauer S.R., Gruzelier, J.H., Zubin, J., Eds. Elsevier, Amsterdam. pp. 397–433.

120. Fenton, W.S., Hibbeln, J., and Knable, M. (2000) Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia. *Biol. Psychiatry* **47**, 8–21.
121. Vaddadi, K.S., Gilleard, C.J., Mindhyam, R.H., and Butler, R. (1986) A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients. *Psychopharmacology* **88**, 361–367.
122. Bourguignon, A. (1984) Trial of evening primrose oil in the treatment of schizophrenia. *L'Encephale* **10**, 241–250.
123. Soulaïrac, A., Lambinet, H., and Neuman, J.C. (1983) Schizophrenia and PGs: therapeutic effects of PG precursors in the form of evening primrose oil. *Ann. Med. Psychol.* **8**, 883–890.
124. Wolkin, A., Jordan, B., Peselow, E., Rubinstein, M., and Rotrosen, J. (1986) Essential fatty acid supplementation in tardive dyskinesia. *Am. J. Psychol.* **143**, 912–914.
125. Puri, B.K., Richardson, A.J., Horrobin, D.F., Easton, T., Saeed, N., Oatridge, A., Hajnal, J.V., and Bydder, G.M. (2000) Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. *Int. J. Clin. Pract.* **54**, 57–63.
126. Richardson, A.J., Easton, T., and Puri, B.K. (2000) Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid. *Eur. Neuropsychopharm.* **10**, 189–193.
127. Peet, M., Brind, J., Ramchand, C.N., Shah, S., and Vankar, G.K. (2001) Two-double blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. *Schizophr. Res.* **49**, 243–251.
128. Peet, M. and Horrobin, D.F. (2002) A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. *J. Psychiat. Res.* **36**, 7–18.
129. Ciapparelli, A., Dell'Osso, L., Pini, S., Chiavacci, M.C., Fenzi, M., and Cassano, G.B. (2000) Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. *J. Clin. Psychiatry* **61**, 329–334.
130. Jann, M.W. (1991) Clozapine. *Pharmacotherapy* **11**, 179–195.
131. Thomas, E.A., Danielson, P.E., Nelson, P.A., Pribyl, T.M., Hilbush, B.S., Hasel, K.W., and Sutcliffe, J.G. (2001) Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy. *J. Neurochem.* **76**, 789–797.
132. Drayna, D., Fielding, C., McLean, J., Baer, B., Castro, G., Chen, E., Comstock, L., Henzel, W., Kohr, W., and Rhee, L. (1986) Cloning and expression of human apolipoprotein D cDNA. *J. Biol. Chem.* **261**, 16535–16539.
133. Lea, O.A. (1988) Binding properties of progesterone-binding cyst protein PBCP. *Steroids* **52**, 337–338.
134. Dille, W.G., Haagensen, D.E., Cox, C.E., and Wells, S.A. (1990) Immunologic and steroid binding properties of the GCDFP-24 protein isolated from human breast gross cystic disease fluid. *Breast Cancer Res. Treat.* **16**, 253–260.
135. Morais-Cabral, J.H., Atkins, G.L., Sanchez, L.M., Lopez-Boado, Y.S., Lopez-Otin, C., and Sawyer, L. (1995) Arachidonic acid binds to apolipoprotein D: implications for the protein's function. *FEBS Lett* **366**, 53–56.
136. Zeng, C., Spielman, A.I., Vowels, B.R., Leyden, J.J., Biemann, K., and Preti, G. (1996) A human axillary odorant is carried by apolipoprotein D. *Proc. Natl. Acad. Sci. U. S. A.* **93**, 6626–6630.
137. Vogt, M. and Skerra, A. (2001) Bacterially produced apolipoprotein D binds progesterone and arachidonic acid, but not bilirubin or E-3M2H. *J. Mol. Recognit.* **14**, 79–86.
138. Horrobin, D.F. (1999) The effects of antipsychotic drugs on membrane phospholipids: a possible novel mechanism of action of clozapine. In *Phospholipid Spectrum Disorder in Psychiatry*. Peet, M, Glen, I., and Horrobin, D.F., Eds. Marius Press, Lancashire, U.K. pp. 113–117.
139. Downes, C.P. (1983) Inositol phospholipids and neurotransmitter-receptor signaling mechanism. *Trends Neurosci.* **6**, 313–316.
140. Berridge, M.J. and Irvine, R.F. (1989) Inositol phosphates and cell signalling. *Nature* **341**, 197–205.
141. Barchas, J.D. and Altemus, M. (1999) Biochemical hypotheses of mood and anxiety disorders. In *Basic Neurochemistry: Molecular, Cellular, and Medical Aspects*, 6<sup>th</sup> Ed. Siegel, G.J., Agranoff, B.W., Albers, W.R., Fisher, S.K., and Uhler, M.D., Eds. Lippincott-Raven Press, New York. pp. 1073–1093.
142. Lachman, H.M. and Papolos, D.F. (1989) Abnormal signal transduction: a hypothetical model for bipolar affective disorder. *Life Sci.* **45**, 1413–1426.
143. Sherman, W.R., Leavitt, A., Honchar, M.P., Hallcher, L.M., and Phillips, B.E. (1981) Evidence that lithium alters phosphoinositide metabolism: chronic administration elevates primarily D-myoinositol-1-phosphate in cerebral cortex of the rat. *J. Neurochem.* **36**, 1947–1951.
144. Joseph, N.E., Renshaw, P.F., and Leigh, Jr., J.S. (1987) Systemic lithium administration alters rat cerebral cortex phospholipids. *Biol. Psychiatry* **22**, 540–544.
145. Chang, M.C.J., Grange, E., Rabin, O., Bell, J.M., Allen, D.D., and Rapoport, S.I. (1996) Lithium decreases turnover of arachidonate in several brain phospholipids. *Neurosci. Lett.* **220**, 171–174.
146. Rintala, J., Seemann, R., Chandrasekaran, K., Rosenberger, T.A., Chang, L., Contreras, M.A., Rapoport, S.I., and Chang, M.C. (1999) 85 kda cytosolic phospholipase A<sub>2</sub> is a target for chronic lithium in rat brain. *Neuroreport* **10**, 3887–3890.

147. Chang, M.C.J., Contreras, M.A., Rosenberger, T.A., Rintala, J.J.O., Bell, J.M., and Rapoport, S.I. (2001) Chronic valproate treatment decreases the *in vivo* turnover of arachidonic acid in brain phospholipids: as a possible common effect of mood stabilizers. *J. Neurochem.* **77**, 796–803.

---

**This article should be referenced as follows:**

Yao, J.K. and Reddy, R.D. (2002) Membrane pathology in schizophrenia: implication for arachidonic acid signaling. *TheScientificWorldJOURNAL* **2**, 1922–1936.

---